Oxford Nanopore Technologies: Daniel Mahony, Guy Harmelin
Oxford Nanopore Technologies has appointed Daniel Mahony as a non-executive director. A senior partner in growth investments at Novo Holdings, Mahony will serve as an Oxford Nanopore board member as it continues to address commercial opportunities in the biopharmaceutical industry. Mahony also currently chairs the UK BioIndustry Association and is a non-executive director of the Wellcome Sanger Institute.
Guy Harmelin, a non-executive director since 2020, has stepped down from the company this week to focus on various other directorship responsibilities.